Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example
Assessment of COPD Therapy From the Physicians Perspective Using Tiotropium as an Example
Sponsor: Boehringer Ingelheim
Listed as NCT01036763, this observational or N/A phase trial focuses on Pulmonary Disease, Chronic Obstructive and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahrensburg, Germany , Amberg, Germany , Arnstadt, Germany , Auerbach, Germany , Augsburg, Germany , Backnang, Germany , Bad Doberan, Germany , Bad Kissingen, Germany , Bad Krozingen, Germany , Bad Kötzting, Germany and 201 more locations